New psoriasis drug shows promise in chinese trial
NCT ID NCT06011733
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tested the drug bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo for 16 weeks. The main goals were to see if bimekizumab could clear at least 90% of psoriasis (PASI90) and achieve clear or almost clear skin (IGA 0/1) compared to placebo. The trial is completed, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bimekizumab
What this could lead to
If successful, bimekizumab could offer a new treatment option for Chinese adults with moderate to severe plaque psoriasis, helping clear skin and reduce symptoms.
What could go wrong
This is a phase 3 trial, but results are not yet published. As with any drug, side effects are possible, and it may not work for everyone. Long-term safety and effectiveness are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ps0041 20022
Hangzhou, China
-
Ps0041 20023
Beijing, China
-
Ps0041 20117
Guangzhou, China
-
Ps0041 20120
Wuhan, China
-
Ps0041 20136
Tianjin, China
-
Ps0041 20184
Shenzhen, China
-
Ps0041 20193
Hangzhou, China
-
Ps0041 20247
Beijing, China
-
Ps0041 20296
Hangzhou, China
-
Ps0041 20306
Beijing, China
-
Ps0041 20308
Shanghai, China
-
Ps0041 20309
Xi'an, China
-
Ps0041 20310
Ningbo, China
-
Ps0041 20311
Guangzhou, China
-
Ps0041 20312
Jinan, China
-
Ps0041 20313
Guangzhou, China
-
Ps0041 20314
Wuxi, China
-
Ps0041 20318
Jinan, China